Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Reshuffles Office Of Generic Drugs To Improve Performance

Executive Summary

The generic drug industry can expect more streamlined reviews as a result of FDA's reorganization of the Office of Generic Drugs, according to the agency.
Advertisement

Related Content

Outgoing OGD Director Outlines Accomplishments During His Tenure
Generic Drugs Gain Status Boost Within CDER
FDA's Office of Medical Policy Grows Into A "Super Office"; DDMAC Gets A Promotion
Generic Drug User Fees Will Begin With The Backlog
Generic Drug User Fees Will Begin With The Backlog
Generic Drug User Fees Will Begin With The Backlog
FDA Reorganization Adds "Directorate" Layer, But Sharpens Agency's Focus
Bye Bye Lipitor: 2011 Presents A Big Opportunity For Generic Drugs
Bye Bye Lipitor: 2011 Presents A Big Opportunity For Generic Drugs

Topics

Advertisement
UsernamePublicRestriction

Register

PS053688

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel